Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib [2]

Journal of Dermatology

Volumn 34, Issue 10, 2007, Pages 724-726

  Woo, Seung Man ^a   Huh, Chang Hun ^a   Park, Kyung Chan ^a   Youn, Sang Woong ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CALCIPOTRIOL; CORTICOSTEROID; DASATINIB; ETRETINATE; IMATINIB;

ABSENCE OF SIDE EFFECTS; ADULT; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DRUG DOSE ESCALATION; HUMAN; LETTER; MALE; PSORIASIS; PUSTULE; ULTRAVIOLET B RADIATION;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PSORIASIS; PYRIMIDINES; SKIN;

EID: 34848844987     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2007.00369.x     Document Type: Letter

References (10)

1. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 344: 1031 1037.
2. Ugurel S, Hildenbrand R, Dippel E, Hochhaus A, Schadendorf D. Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer 2003 88: 1157 1159.
3. Brazzelli V, Prestinari F, Roveda E et al. Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases. J Am Acad Dermatol 2005 53: S240 S243.
4. Gambillara E, Laffitte E, Widmer N et al. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia., Dermatology 2005 211: 363 365.
5. Valeyrie L, Bastuji-Garin S, Revuz J et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003 48: 201 206.
6. Hsiao LT, Chung HM, Lin JT et al. Stevens-Johnson syndrome after treatment with STI571. Br J Haematol 2002 117: 620 622.
7. Miyagawa S, Fujimoto H, Ko S, Hirota S, Kitamura Y. Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br J Dermatol 2002 147: 406 407.
8. Pietras K, Ostman A, Sjoquist M et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001 61: 2929 2934.
9. Seggewiss R, Lore K, Greiner E et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005 105 (6 2473 2479.
10. Gao H, Lee B, Talpaz M, Donato NJ et al. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 2005 19: 1905 1911.